Benzodiazepine derivatives targeting GABA A gamma1 PAMs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autism spectrum disorders (ASD) and related conditions lack effective pharmacological options for core symptoms, with existing therapies providing inadequate relief and often accompanied by significant side effects, and there is a need for targeted modulation of GABAergic signaling to address imbalances in inhibitory neurotransmission.
Innovation Solution
Development of selective GABA A γ1 receptor positive allosteric modulators (PAMs) that enhance GABAergic currents specifically at γ1-containing receptors, offering high efficacy and binding selectivity for α5γ1, α2γ1, and α1γ1 subtypes over y2-containing subtypes, thereby restoring inhibitory balance in key brain regions without the side effects of non-selective benzodiazepines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective benzodiazepines are used to treat ASD and anxiety disorders, then GABAergic signaling is enhanced, but sedation and other adverse effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures that confer selective affinity for γ1-containing GABA A receptor subtypes. The compounds contain specific substituent patterns (R1-R7 groups) that enable preferential binding to α2β2γ1, α3β2γ1, and α5β2γ1 subtypes while avoiding γ2-containing subtypes, thereby achieving localized modulation of GABAergic signaling in limbic brain regions without widespread CNS depression
Solution Approach 2:
The patent segments the GABA A receptor population by exploiting subunit composition differences. By designing PAMs that specifically target γ1-containing receptors (which are enriched in limbic regions) versus γ2-containing receptors (which mediate sedative effects), the invention divides the therapeutic action from the adverse effects, allowing selective enhancement of inhibitory neurotransmission in anxiety and ASD-related circuits without global sedation
2Reliability
If existing therapies are used for ASD core symptoms, then some symptom relief is provided, but the relief is inadequate and side effects are significant
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations on the benzodiazepine core structure) to optimize the balance between therapeutic efficacy and selectivity. By adjusting parameters such as R1 (aryl or heteroaryl groups), R2 and R6 (hydrogen, halogen, or alkyl groups), and R3-R7 (various substituents), the invention fine-tunes the compounds' affinity for γ1-containing receptors while minimizing off-target effects
Data Source
AI summary
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds.